MedTrace Logo

Pharmacogenomics and Post-Operative Nausea and Vomiting

NCT03503292 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2020-10-28

Study results available
· View outcomes & findings →

Summary

The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.

Conditions

  • Postoperative Nausea

Interventions

DRUG

Granisetron

Rapid metabolizer will receive 1mg IV Granisetron

DRUG

Ondansetron

Poor or normal metabolizers will receive 4mg Ondansetron IV

Sponsors & Collaborators

Principal Investigators

  • Yvette N Martin, MD, PhD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-02
Primary Completion
2019-12-30
Completion
2019-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03503292 on ClinicalTrials.gov